SEC Tracker
Get the app
REGN · XBRL financial data

Regeneron Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (REGN's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue from contracts with customers3,434*3,1453,5473,7213,789*3,0293,6763,7543,884*3,6054,2915,116
Research and development1,177*1,2481,2001,2721,412*1,3271,4221,4751,626*1,5441,6321,795
Selling, general and administrative738*689759714792*633634658775*648662678
Other operating income (expense)1*(15)(15)(8)(16)*00100*——0
Operating income (loss)973*7511,0701,180990*5921,0801,027880*6431,2942,048
Interest expense18*16151411*941912*131111
Other income (expense)193*(35)573327(22)*322443756176*201245247
Income tax expense (benefit)(12)*(21)19615240*96127303199*104231335
Net income (loss)1,160*7221,4321,341918*8091,3921,460845*7271,2971,949
Earnings per share, basic USD per share10.90*6.7013.2512.408.53*7.5813.2414.098.20*6.9912.6219.16
Earnings per share, diluted USD per share10.22*6.2712.4111.548.07*7.2712.8113.627.86*6.7512.2318.45
Weighted average shares, basic millions of shares106*108108108108*107105104103*104103102
Weighted average shares, diluted millions of shares114*115115116114*111109107107*108106106

Balance sheet

CSV

Fiscal quarters (REGN's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents2,7302,6021,9212,0122,4883,0901,9962,5063,1182,9632,4563,659
Marketable securities8,1157,9187,8887,7856,5245,2595,4745,9375,4875,7915,5395,642
Marketable securities, non-current5,3976,9797,7228,4918,9009,27610,05810,28610,2619,7869,8289,557
Accounts receivable5,6675,2225,7176,1076,2125,5615,6105,6875,7415,7316,5657,579
Inventory2,5812,7152,8743,0183,0873,1923,2063,2543,2013,1043,0842,895
Prepaid and other current assets3874156824123494695745964756218021,021
Total current assets19,47918,87219,08219,33418,66117,57216,86017,98118,02218,20918,44620,795
Right-of-use asset78———217———246———
Total assets33,08034,37036,08737,44237,75937,54538,21940,16940,55940,86941,73144,405
Accounts payable6076715624977907067249049391,0271,1591,140
Total current liabilities3,4233,5813,5093,6613,9443,5673,6674,4254,3685,1085,5316,202
Long-term debt1,9831,9831,9841,9841,9841,9851,9851,9861,9861,9861,9871,987
Lease liability, non-current69———204———229———
Total liabilities7,1077,3797,8818,1168,4068,1588,2809,2129,3029,44510,01910,907
Retained earnings27,26027,98229,41530,75531,67332,38433,68035,04635,79736,42437,62139,472
Total stockholders' equity25,97326,99128,20629,32629,35429,38829,93930,95831,25731,42431,71133,499
Total liabilities and equity33,08034,37036,08737,44237,75937,54538,21940,16940,55940,86941,73144,405

Cash flows

CSV

Fiscal quarters (REGN's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)1,160*7221,4321,341918*8091,3921,460845*7271,2971,949
Stock-based compensation240*230223*225*304*256252*237*249*257243*256*
Depreciation and amortization113*114121*122*126*127135*137*145*123124*121*
Net cash from operating activities1,090*1,513354*1,291*1,263*1,0451,144*1,619*1,171*1,079813*1,783*
Net cash from investing activities(66)*(1,687)(557)*(574)*351*648(1,094)*(403)*220*(429)(93)*(288)*
Proceeds from issuing common stock301*682438*255*91*6132*40*504*16349*301*
Share repurchases289*291604*735*973*1,0411,062*664*672*7941,169*400*
Dividends paidyear only00*0*0*9493*91*93*9897*96*
Net cash from financing activities(446)*47(478)*(634)*(1,136)*(1,089)(1,128)*(718)*(780)*(802)(1,225)*(290)*
Net change in cash578*(128)(682)*84*477*604(1,077)*498*611*(153)(505)*1,206*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingQuarter
Regeneron Pharmaceuticals3,6595,1161,783*not reported 10-QSep 30, 2026
Zoetis1,4762,468655*413.2M 10-QJun 30, 2026
Idexx Laboratories1981,214450*78.8M 10-QSep 30, 2026
Alnylam Pharmaceuticals1,7541,458341*133.9M 10-QSep 30, 2026
Bristol Myers Squibb9,57413,0694,181*2.0B 10-QSep 30, 2026
Gilead Sciences6,4378,3005,035*1.2B 10-QSep 30, 2026
Vertex Pharmaceuticals4,9793,441643*253.5M 10-QSep 30, 2026
Pfizer1,82416,5835,375*5.7B 10-QSep 27, 2026
INSMED397524(36)*219.4M 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.